MAEL

MAEL is a germ-cell and cancer-associated protein that links transposon silencing and nuage/mitochondrial biology to oncogenic protein turnover and signaling (PMID:23412502, PMID:27926513, PMID:36866961). In spermatogenic cells it localizes to nuage structures (intermitochondrial cement, perinuclear granules, chromatoid bodies) and co-localizes with MIWI, and in human spermatozoa it localizes to mitochondria where it binds GPX4 and UBL4B to support mitochondrial function and ATP production (PMID:23412502, PMID:36779514). MAEL restrains retrotransposon activity in both germ cells and cancer cells, and its own expression is controlled by CpG-island promoter methylation: demethylation upregulates MAEL while targeted promoter hypermethylation suppresses it and de-represses LINE-1 (PMID:19693694, PMID:29095993, PMID:27926513). In cancer, MAEL acts as an oncogene by promoting chaperone-mediated autophagy-dependent degradation of target proteins—it bridges the metabolic enzymes citrate synthase and fumarate hydratase to HSPA8 via its MAEL and HMG domains for lysosomal degradation, and similarly drives lysosomal degradation of the phosphatase ILKAP to amplify p38/CHK1/RSK2 phosphorylation (PMID:36866961, PMID:29371914). MAEL further interacts with Snail to repress the E-cadherin promoter and promote EMT, transcriptionally activates PTGS2 to engage IL-8/AKT/NF-κB/STAT3 stemness and drug-resistance signaling, and protects genomic integrity such that its knockdown triggers ATM-dependent DNA damage responses, ROS accumulation, apoptosis, and senescence (PMID:27537253, PMID:35740546, PMID:27926513). MAEL also associates with stress granule components including PABPC1 under oxidative stress (PMID:24189637).

1. 2009 Medium

   Established that MAEL expression is epigenetically silenced in somatic/cancer cells, explaining its normally germline-restricted pattern and its re-expression in tumors.

   Evidence Promoter CpG-island mapping and 5'-Aza-2-Deoxycytidine demethylation with RT-PCR in cancer cell lines

   PMID:19693694

   Open questions at the time

   • Does not identify the methyltransferases or demethylation context in vivo
   • Does not link methylation status to specific tumor types or outcomes
2. 2013 Medium

   Defined MAEL's germline subcellular niche, placing it in nuage and chromatoid bodies alongside MIWI, the structural basis for a piRNA-pathway role.

   Evidence Immunofluorescence and immunoelectron microscopy with MIWI/DDX4/DDX25 co-localization in rat testis

   PMID:23412502

   Open questions at the time

   • Co-localization does not demonstrate direct biochemical interaction with MIWI
   • Functional contribution to piRNA biogenesis not tested here
3. 2013 Low

   Showed MAEL is functionally required in the female germline, extending its role beyond spermatogenesis to oogenesis.

   Evidence siRNA knockdown in mouse fetal ovary explants and ESC-to-germ-cell differentiation assays

   PMID:23410657

   Open questions at the time

   • Single loss-of-function method without rescue
   • Molecular mechanism of oocyte differentiation defect undefined
4. 2013 Medium

   Identified a stress-granule association for MAEL in cancer cells, suggesting RNP/RNA-regulatory engagement outside germ cells.

   Evidence Co-IP/Nano-LC-MS/MS interactome with reciprocal anti-tag co-IP and PABPC1 co-localization under oxidative stress

   PMID:24189637

   Open questions at the time

   • Functional consequence of SG localization not established
   • Direct versus indirect (RNA-bridged) nature of interactions unresolved
5. 2016 Medium

   Connected MAEL to EMT by showing it cooperates with Snail to repress E-cadherin, providing a transcriptional mechanism for its pro-metastatic activity.

   Evidence Co-IP, immunofluorescence co-localization, and E-cadherin promoter luciferase reporter in colorectal cancer cells

   PMID:27537253

   Open questions at the time

   • MAEL's molecular role at the promoter (cofactor vs adaptor) unclear
   • Direct DNA-binding versus Snail-dependent recruitment not distinguished
6. 2017 Medium

   Reframed MAEL as a guardian of genome integrity in cancer, with knockdown unleashing ATM-dependent damage responses and overexpression repressing retrotransposons and senescence.

   Evidence siRNA across cancer lines, ATM-dependency epistasis, ROS/DNA-damage markers, Myc/Ras transformation and retrotransposon reporter assays

   PMID:27926513

   Open questions at the time

   • Molecular mechanism by which MAEL suppresses transposons/ROS not resolved
   • Link between transposon silencing and DNA-damage suppression inferred, not directly demonstrated
7. 2017 Medium

   Identified ILKAP as a degradation target of MAEL, providing a phosphatase-loss mechanism for downstream oncogenic kinase signaling.

   Evidence Knockdown/overexpression, xenografts, IP, and adenoviral ILKAP rescue in gastric cancer cells

   PMID:29371914

   Open questions at the time

   • Degradation route (CMA vs other lysosomal) not dissected here
   • Direct binding interface not mapped
8. 2017 Medium

   Demonstrated causally that MAEL promoter methylation controls transposon silencing, tying the epigenetic regulation of MAEL to its biological function.

   Evidence Targeted promoter methylation in NCI-H358 cells with luciferase reporter and LINE-1 RT-qPCR

   PMID:29095993

   Open questions at the time

   • Mechanism by which MAEL protein represses LINE-1 not addressed
   • In vivo relevance to germ cells not tested
9. 2022 Medium

   Defined a PTGS2-centered stemness/drug-resistance axis downstream of MAEL, linking it to IL-8/AKT/NF-κB/STAT3 signaling.

   Evidence MAEL knockout HCC cells with PTGS2 rescue, signaling western blots, and IL-8 ELISA

   PMID:35740546

   Open questions at the time

   • How MAEL transcriptionally activates PTGS2 mechanistically is unknown
   • Direct versus indirect transcriptional control not established
10. 2022 Low

    Linked MAEL to drug-efflux-mediated resistance, broadening its oncogenic repertoire to chemoresistance.

    Evidence RNAi/overexpression with MRP/LRP westerns and LY411575 sensitivity in T-ALL/T-iPSC model

    PMID:35488386

    Open questions at the time

    • Single method type without rescue
    • Mechanism connecting MAEL to MRP/LRP regulation unknown
11. 2022 Low

    Placed MAEL in an immune-evasion pathway, regulated by morphine via Nrf2/PTEN and controlling checkpoint molecule expression.

    Evidence Western/RT-qPCR/ELISA/flow cytometry with siRNA and PTEN overexpression and LDH cytotoxicity in lung cancer cells

    PMID:36476246

    Open questions at the time

    • Mechanistic link is correlative across pathway components
    • Direct MAEL targets in immune checkpoint regulation not identified
12. 2023 Medium

    Established the molecular logic of MAEL-driven chaperone-mediated autophagy, showing it bridges metabolic enzyme substrates to HSPA8 via distinct domains for lysosomal degradation.

    Evidence Reciprocal co-IP, domain mapping, and lysosomal/macroautophagy/proteasome inhibitor panel in breast cancer cells

    PMID:36866961

    Open questions at the time

    • Substrate selectivity rules beyond CS/FH not defined
    • No structural model of the MAEL–HSPA8–substrate ternary complex
13. 2023 Medium

    Defined a mitochondrial function for MAEL in sperm, binding GPX4 and UBL4B, linking it to ATP production and asthenozoospermia.

    Evidence Immunogold localization, siRNA knockdown with mitochondrial/ATP assays, and co-IP in human sperm/cells

    PMID:36779514

    Open questions at the time

    • Whether GPX4/UBL4B binding is regulatory or structural is unresolved
    • Causal contribution to clinical asthenozoospermia not proven

• How MAEL's germline nuage/piRNA functions mechanistically connect to its cancer-cell roles in CMA-mediated degradation, transcriptional regulation, and signaling remains unresolved.
• No structural data on MAEL or HMG domain function across contexts
• No unifying model linking transposon silencing to oncogenic protein degradation
• Direct piRNA-pathway biochemistry for human MAEL not established in the corpus